SCHEMBL2223009

SCHEMBL2223009

[CH2]OP(=O)(OC(C)(C)C)OC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486485 0.81 TSHR (0.31) TSHRTDP1
Fluoride SCHEMBL12079669 0.78
Phosphine SCHEMBL28531842 0.78 TSHR (0.35) TSHR
SCHEMBL2871050 0.75
SCHEMBL3346640 0.73 ALDH1A1 (0.33) TSHR
SCHEMBL2231830 0.73 ALDH1A1 (0.33) TSHR
SCHEMBL21815536 0.72 LMNA (0.33)
SCHEMBL31243806 0.71
SCHEMBL29253528 0.71
SCHEMBL29129698 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-06-20 US disclosed
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD. (CN) 2024-06-13 US disclosed
EP-4375279-A2 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. (US) 2024-05-29 EP disclosed
US-20240150351-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. 2024-05-09 US disclosed
CN-117946166-A COT modulators and methods of use thereof 吉利德科学公司 2024-04-30 CN disclosed
CN-117946167-A COT modulators and methods of use thereof 吉利德科学公司 2024-04-30 CN disclosed
US-20240132527-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION GILEAD SCIENCES, INC. 2024-04-25 US disclosed
WO-2024073559-A1 BICYCLIC COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-04-04 WO disclosed
EP-3983064-B1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES INC (US) 2024-03-06 EP disclosed
US-20240043458-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2024-02-08 US disclosed
US-10385055-B2 Tricyclic gyrase inhibitors MERCK SHARP & DOHME CORP. (US) 2019-08-20 US disclosed
EP-3114126-B1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS IDORSIA PHARMACEUTICALS LTD (CH) 2018-10-31 EP disclosed
US-10106544-B2 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents IDORSIA PHARMACEUTICALS LTD (CH) 2018-10-23 US disclosed
US-20170107223-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS IDORSIA PHARMACEUTICALS LTD (CH) 2017-04-20 US disclosed
EP-3114126-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS Actelion Pharmaceuticals Ltd (CH) 2017-01-11 EP disclosed
US-20160222015-A1 TRICYCLIC GYRASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-08-04 US disclosed
EP-3008062-A2 PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2016-04-20 EP disclosed
WO-2015132228-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS ACTELION PHARMACEUTICALS LTD (CH) 2015-09-11 WO disclosed
WO-2014198647-A2 PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-12-18 WO disclosed
WO-2011084846-A1 QUATERNARY AMMONIUM SALT PRODRUGS ALKERMES, INC. (US) 2011-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10385055-B2 Tricyclic gyrase inhibitors TOP1, TOP2A, TOP2B TSHR 4555/4885TDP1 11/4885
US-20240190875-A1 SPIROINDOLINE DERIVATIVE, AND PREPARATION METHOD AND MEDICAL USE THEREOF GHSR, GHRHR, NR3C2 TSHR 44/4885TDP1 4090/4885
US-10106544-B2 1,2-dihydro-3H-pyrrolo[1,2-C]imidazol-3-one derivatives and their use as antibacterial agents CCNI, H1-0, H1-3 TSHR 2525/4885TDP1 3114/4885
US-20160222015-A1 TRICYCLIC GYRASE INHIBITORS TOP1, TOP2A, TOP2B TSHR 4555/4885TDP1 11/4885
US-20240199589-A1 GLP-1R MODULATING COMPOUNDS GLP1R, GIPR, GPR119 TSHR 120/4885TDP1 3351/4885
US-20240150351-A1 BICYCLIC COMPOUNDS SLC10A1, PKD1, CYP11B2 TSHR 3288/4885TDP1 3822/4885
US-20240043458-A1 COT MODULATORS AND METHODS OF USE THEREOF BRDT, THRB, HCCS TSHR 11/4885TDP1 1212/4885
US-20170107223-A1 1,2-DIHYDRO-3H-PYRROLO[1,2-C]IMIDAZOL-3-ONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS CCNI, H1-0, H1-3 TSHR 2525/4885TDP1 3114/4885
US-20240132527-A1 THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION CD4, HAVCR2, MAVS TSHR 4869/4885TDP1 1611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.